Revvity Inc. (NYSE:RVTY) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Revvity Inc. (NYSE:RVTY) have earned an average recommendation of “Hold” from the sixteen ratings firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $108.9167.

Several brokerages recently weighed in on RVTY. Robert W. Baird set a $117.00 price objective on shares of Revvity in a report on Wednesday, May 6th. The Goldman Sachs Group decreased their price objective on shares of Revvity from $110.00 to $95.00 and set a “neutral” rating for the company in a report on Tuesday, April 14th. Wolfe Research initiated coverage on Revvity in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Barclays raised their price target on Revvity from $95.00 to $105.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 7th. Finally, Stifel Nicolaus dropped their target price on shares of Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a report on Wednesday, May 6th.

Revvity Price Performance

Shares of RVTY stock opened at $110.56 on Friday. Revvity has a one year low of $81.22 and a one year high of $118.30. The firm has a market cap of $12.33 billion, a price-to-earnings ratio of 52.90, a P/E/G ratio of 2.17 and a beta of 1.09. The stock’s fifty day simple moving average is $104.90 and its 200 day simple moving average is $99.61. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.72 and a quick ratio of 1.41.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.04. The firm had revenue of $711.12 million for the quarter, compared to analyst estimates of $704.07 million. Revvity had a net margin of 8.26% and a return on equity of 8.00%. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same period in the previous year, the business earned $1.01 earnings per share. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, analysts expect that Revvity will post 5.25 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 7th. Investors of record on Friday, July 17th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. Revvity’s dividend payout ratio is presently 13.40%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Ascentis Independent Advisors bought a new stake in shares of Revvity in the first quarter worth $29,000. CYBER HORNET ETFs LLC acquired a new stake in Revvity in the 2nd quarter valued at $32,000. Cromwell Holdings LLC lifted its position in Revvity by 141.4% during the 4th quarter. Cromwell Holdings LLC now owns 338 shares of the company’s stock worth $33,000 after buying an additional 198 shares in the last quarter. MUFG Securities EMEA plc bought a new stake in Revvity during the 2nd quarter worth about $34,000. Finally, SJS Investment Consulting Inc. boosted its stake in shares of Revvity by 5,210.0% during the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after buying an additional 521 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.